Company profile
MJardin Group, Inc.
OTC: MJARF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Toronto, ONReports USD
#653 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ —GM —SS 29
v0.1 · 5/100 weight · pillars only
↑ return on assets, growth stability · ↓ revenue growth (YoY), Piotroski F
Methodology →Revenue TTM
$4.8M
Rev growth YoY (TTM)
-39.0%
Net income (FY)
-$26.0M
Employees
—
as of 2026-08-28
Market cap
$90.1k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$8.5M11.4M CAD2020
Net income-$26.0M-34.8M CAD2020
Operating income-$10.9M-14.6M CAD2020
Total assets$79.2M100.8M CAD2020
Liabilities$149.7M190.5M CAD2020
Equity-$67.6M-86.0M CAD2020
Revenue trend
FY2017 – FY2020 · USD
FY17
FY18
FY19
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is MJardin Group, Inc.’s revenue?
MJardin Group, Inc. booked $8.5M in FY2020 revenue, contracting 58% year over year — slower than 84% of Healthcare companies we track, at a -304.6% net margin.
Peers · Healthcare
InspireMD, Inc.60CMilestone Scientific Inc.41DHerbal Dispatch Inc.52DAspyra Inc.——Nuwellis, Inc.43DSolid Biosciences Inc.41DKey facts
CEOAli Mahdavi
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersToronto, ON
ExchangeOTC: MJARF
Employees—
IPO date2018-11-16
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.